Breast Cancer

Biotechnology company receives approval for breast cancer screening trials

Published in Gene Therapy Weekly, October 14th, 2004

Power3 Medical Products, Inc., (OTCBB: PWRM) announced that the company was notified that the institutional review board (IRB) at the Women's Hospital of Texas granted approval to the Clinical Research Center of Houston, Obstetrical and Gynecological Associates (OGA), to begin a clinical validation study on the early detection breast cancer NAFTest.

The company's NAFTest for the detection, diagnosis, and monitoring of breast cancer utilizes fluids from the breast called nipple aspirates to identify groups of breast cancer proteins. Previous studies conducted by Power3 Medical using proteomic analysis of nipple aspirate fluid (NAF) found differences in the protein...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-10-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry